GlassScriptPhysician profile
Leslie A Bebb
NPI 1962699389
$2,741.30
in general payments reported to CMS, 2019-2025
27 companies · $862 in 2025
The $862 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.27 · 2022: $294 · 2023: $783 · 2024: $729 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,373.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $512.48 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $387.92 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $214.47 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Phathom Pharmaceuticals, INC. | $167.58 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $147.51 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $128.55 | 2022-2023 | |
| Gilead Sciences, INC. | $117.86 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $106.50 | 2023-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $89.69 | 2022-2025 | Rebyota |
| Celgene Corporation | $85.79 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $80.75 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $72.41 | 2023-2024 | Linzess |
| Novo Nordisk INC | $67.26 | 2025 | Wegovy |
| Qol Medical, LLC | $61.72 | 2024-2025 | Sucraid, Sucraid |
| Orphalan INC | $58.67 | 2024 | Cuvrior |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $55.51 | 2024-2025 | Terlivaz |
| Lilly USA, LLC | $47.63 | 2024 | Omvoh |
| Exact Sciences Corporation | $47.12 | 2024-2025 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $46.26 | 2023-2024 | Dupixent |
| Evoke Pharma, INC. | $45.42 | 2023 | Gimoti |
| Aimmune Therapeutics, INC. | $34.17 | 2025 | Zenpep |
| Amgen INC. | $31.08 | 2025 | |
| Redhill Biopharma INC. | $30.69 | 2023 | Talicia, Movantik, Aemcolo |
| Celltrion USA INC. | $30.18 | 2025 | Vegzelma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.06 | 2023 | Trulance |
| Pentax of America, INC. | $25.03 | 2024 | Pentax Medical, Inspira, C2 Cryoballoon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.99 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Bebb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.